Alpha 1a adrenergic receptor antagonists
CA 2294346 A1 · Owner: Merck & Co. Inc. · Inventors: Bock, Mark G.; Patane, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to nitrogen containing heterocyclic compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenoceptor antagonists. More particularly, the compounds of the present invention are useful for treating benign prostatic hyperplasia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 17, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 17, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 17, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.